Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.02.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Marco Zampoli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and University of Cape Town, 5th Floor ICH Building, Klipfonte…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Clarithromycin, Aminophenols, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVE: Access to highly effective modulator therapies (HEMT) in resource-limited countries is limited by prohibitive cost and restrictive patents. We report the clinical outcomes of a cost-reduction strategy in South Africa (SA), where generic elexacaftor/tezacaftor/ivacaftor (gETI) was pharmacokinetically enhanced with clarithromycin (gETI/c) for people with CF (pwCF) eligible for HEMT. METHODS: A multi-center observational study from December 2021 to May 2024. Analysis of variance (ANOVA) and linear mixed effects analyses were conducted to describe and compare change in sweat chloride (SC), FEV1pp, BMI (m/kg2) and adverse events (AE) over 18-months follow-up for different gETI dose categories: a) standard, full or b) modulator sparing dose (gETI/c at 25-50 % recommended dose, twice/thrice weekly). RESULTS: 70/413 (17 %) eligible pwCF [median age 27 years (range 6-52); 68 (97 %) with ≥ one copy F508del] received gETI with standard (n = 38) or modulator-sparing doses (n = 32); 29 changed dosing regimens across the study period. The overall mean (SD) reduction in SC after 1-month of treatment was -52.9 (16.9) mmol/L (p < 0.001), with no evidence of difference between dose groups (p = 0.2). Overall mean (SD) FEV1pp and BMI increased at 1-month by 14.9 (95 % CI 11.49-18.40) and 0.84 (95 % CI 0.16-1.49), respectively. Improvements in FEV1pp and BMI were sustained throughout follow-up, with no evidence of difference between dosing groups. No serious AEs were reported. CONCLUSION: Our experience with gETI is similar to real-world reports using the originator product. Boosting ETI with CYP3A-inhibitors is a safe and effective strategy to increase access to ETI in settings where access to HEMT is restricted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and University of Cape Town, 5th Floor ICH Building, Klipfontein Rd Rondebosch, Cape Town 7700, South Africa. Electronic address: m.…
- Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and University of Cape Town, 5th Floor ICH Building, Klipfontein Rd Rondebosch, Cape Town 7700, South Africa.
- Adult Cystic Fibrosis Clinic, Netcare Milpark Hospital, Johannesburg, South Africa.
- Mediclinic Panorama Hospital, Cape Town, South Africa.
- Department of Medicine, Division of Pulmonology and UCT Lung Institute, Groote Schuur Hospital and University of Cape Town, South Africa.
- Netcare Linksfield Hospital, Johannesburg, South Africa.
Zitieren
APA
Zampoli, M., Verstraete, J., Baird, C., Biebuyck, T., Calligaro, G., Coetzee, M., Els, C., Frauendorf, M., Gebers, P., Morrow, B., Richards, D., Truter, H., & Hill, A. (2025). Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.02.002
Vancouver
Zampoli M, Verstraete J, Baird C, Biebuyck T, Calligaro G, Coetzee M, et al. Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.02.002
BibTeX
@article{Zampoli2025,
author = {Zampoli, Marco and Verstraete, Janine and Baird, Cathy and Biebuyck, Tony and Calligaro, Greg and Coetzee, Marina and Els, Carla and Frauendorf, Marlize and Gebers, Paul and Morrow, Brenda and Richards, Dave and Truter, Hanri and Hill, Andrew},
title = {Real-world outcomes of generic elexacaftor/tezacaftor/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.02.002}
}
EUVIMED